Muscle-invasive Bladder Cancer research hub
9 indexed studies · 1 currently recruiting
- recruitingPHASE2
Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations
This study looks at new treatments for a type of bladder cancer that has spread into the muscle. It tests a drug called erdafitinib, either on its own or with another drug called cetrelimab, before surgery. It's for people whose cancer has a specific gene change and can't have standard chemotherapy.
France · Italy · Spain - active not recruitingPHASE1
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer
This study is for people with bladder cancer that's spread and hasn't responded to previous treatment. It tests several new drug treatments, alone or in combination, to see if they're safe and effective. Doctors will check your tumour for specific changes to decide which treatment might be best for you.
United States · Canada · France - active not recruitingPHASE3
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
This study looks at a new way to treat muscle-invasive bladder cancer using a drug called Durvalumab alongside standard chemotherapy. It aims to see if this combination, given before and after surgery, can improve treatment outcomes and safety for patients.
United States · Australia · Belgium - authorisedTherapeutic exploratory (Phase II)
Bladder Preservation with Sacituzumab Govitecan + Zimberelimab for MuscleInvasive Bladder cancer in cisplatin-unfit and unwilling for cystectomy patients: phase II trial (preSAVE trial)
This study looks at new treatments (Zimberelimab and Trodelvy) for muscle-invasive bladder cancer in people who can't have surgery or choose not to. We want to see how well these drugs can help control the cancer and avoid surgery.
Italy - active not recruitingPHASE3
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
This study looks at a medicine called atezolizumab for people with a type of bladder cancer that has spread into the muscle. It checks if this medicine, given after surgery, can stop the cancer from coming back in those who show signs of tiny cancer cells in their blood.
United States · Argentina · Belgium - active not recruitingPHASE3
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
This study looks at treating muscle-invasive bladder cancer. It compares standard chemotherapy with chemotherapy plus a new immunotherapy drug called nivolumab, given before and after surgery. The aim is to see if adding nivolumab helps more people.
United States · Argentina · Australia - ongoing, recruitingTherapeutic exploratory (Phase II)
An open label, single-arm, phase 2 study of neoadjuvant sacituzumab govitecan, before radical cystectomy, for patients with muscle-invasive bladder cancer who cannot receive or refuse cisplatin-based chemotherapy
This study is looking at a new medicine called Trodelvy for people with a type of bladder cancer that has grown into the muscle of the bladder. It's for those who can't have or don't want standard chemotherapy. Researchers want to see if Trodelvy helps shrink the cancer before surgery.
Italy - active not recruitingPHASE3
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
This study looks at new drug combinations for bladder cancer that has spread into the muscle. It compares them to standard treatment for people who can't take or don't want cisplatin chemotherapy before surgery to remove their bladder. The aim is to find more effective and safe options.
United States · Argentina · Austria - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS- 986205, Followed by Continued Post- Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer
This study is looking at new ways to treat bladder cancer that has grown into the muscle. It compares standard chemotherapy with chemotherapy plus new immunotherapy drugs (like Nivolumab) before and after surgery, to see which approach works best and is safest.
Germany · Norway · France